Previsioni
| Acquista |
3 |
| Mantieni |
11 |
| Vendi |
2 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Galapagos records 91% drop in revenue and launches strategic realignment
Galapagos reported a 91.3% decline in revenue for Q1 2026 to €6.5 million, primarily due to the loss of income from the agreement with Gilead. Despite the revenue shock, the company posted a net profit of €14.5 million, driven by positive currency effects and financial results. Management announced a comprehensive transformation including a renaming to Lakefront Biotherapeutics, a focus on innovative therapies such as Gamgertamig, and consideration of a share buyback as part of a new Gilead agreement. For 2026, Galapagos expects high expenses (including a prepayment to Gilead and costs related to the acquisition of Ouro Medicines) and forecasts year-end cash of between €1.975 billion and €2.05 billion. » Altro su de.investing.com
RBC cuts Galapagos NV price target to $28, keeps Sector Perform ahead of Q1
RBC Capital Markets reduced its price target for Galapagos NV from $33 to $28 while maintaining a Sector Perform rating, citing seasonal pressures including reimbursement resets, gross-to-net dynamics, fewer selling days and potential weather-related disruptions. The bank noted that rising M&A activity and clearer drug-pricing expectations could help offset near-term volatility. Separately, Galapagos and Gilead agreed a binding framework related to Gilead’s acquisition of Ouro Medicines that expands collaboration rights and includes funding and operational arrangements. » Altro su finance.yahoo.com
Galapagos signs agreement with Gilead on Ouro Medicines assets
Galapagos reached a binding agreement with Gilead tied to Gilead’s acquisition of Ouro Medicines, obtaining licenses to key IP, gamgertamig (a BCMAxCD3 T cell engager) and additional preclinical programs, plus related facilities and staff. The deal makes Galapagos responsible for early-stage development while later-stage costs and global commercialization (outside certain territories) will be shared with Gilead; Galapagos can receive milestone payments and tiered royalties of 20–23% on net sales. The company can independently deploy at least $500M of cash, including up to $150M for potential share buybacks. Gamgertamig has FDA Fast Track and Orphan Drug designations for AIHA and ITP and may enter registrational studies as early as 2027. Galapagos also proposed appointing Gino Santini as non-executive independent director and future chair, subject to shareholder approval. » Altro su finance.yahoo.com
Galapagos and Gilead collaborate on Gamgertamig, unlock $500M and target 2027 registrational trials
Galapagos struck a binding collaboration with Gilead on BCMA x CD3 T‑cell engager Gamgertamig, with the companies splitting an upfront payment and milestone payments (including references to ~$1.675 billion and up to $500 million) and Galapagos eligible for up to $100 million in development milestones. The deal amends the legacy OLCA and unlocks an additional $500 million of Galapagos cash (including up to $150 million potentially available for return of capital); Gilead will hold commercialization rights outside Greater China while Galapagos gets 20%–23% royalties. Gamgertamig is in phase 1b (over 60 autoimmune patients treated, >160 across all trials), has Fast Track and Orphan designations for hemolytic anemia and ITP, and could enter registrational studies as early as 2027. Galapagos will fund development through initiation of registrational studies, after which costs are shared, and management says the transaction preserves strategic flexibility and leaves the majority of cash available for other opportunities. » Altro su finance.yahoo.com
Galapagos exits cell therapy, shifts to business development with ~€3bn cash
Galapagos is winding down its cell therapy program and refocusing on business development in inflammation & immunology and oncology, backed by a refreshed leadership team and board. The company ended 2025 with about €2.998 billion in cash after recognizing €1.069 billion of deferred income tied to Gilead and taking ~€399.8 million of wind‑down and restructuring charges. TYK2 inhibitor GLPG3667 showed positive Phase 2 topline results in dermatomyositis and SLE, but Galapagos says it lacks full Phase 3 infrastructure and is seeking partners to advance the program. Management expects the cell therapy wind‑down to be largely complete by Q3 2026, anticipates one‑time restructuring cash costs of €125–175 million in 2026, and aims to be cash‑flow neutral to positive by year‑end 2026. » Altro su finance.yahoo.com
Dati finanziari
Nell'ultimo trimestre, Galapagos ha registrato ricavi pari a 7,42 Mln € e un utile netto di -2,61 Mln €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 7,42 Mln | 89,58% |
| Utile lordo | 3,82 Mln | 93,67% |
| Utile netto | -2,61 Mln | 98,71% |
| EBITDA | -39,84 Mln | 78,98% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 2,11 Mld € |
Numero di azioni | 65,9 Mln |
Massimo/minimo a 52 settimane | 31,99 € - 23,88 € |
| Dividendi | No |
Beta | 0,11 |
Rapporto P/E | 4,18 |
Rapporto PEG | -0,11 |
Rapporto P/B | 0,63 |
Rapporto P/S | 1,94 |
Profilo aziendale
Galapagos NV, una società biofarmaceutica integrata, si occupa della scoperta, dello sviluppo e della commercializzazione di vari farmaci per soddisfare gravi bisogni medici non ancora coperti. I suoi prodotti in pipeline includono filgotinib, un inibitore di JAK1 che si trova in varie fasi di sperimentazioni cliniche per il trattamento dell'artrite reumatoide, della malattia di Crohn, della colite ulcerosa, della malattia di Crohn dell'intestino tenue, della malattia di Crohn fistolizzante, della spondilite anchilosante, dell'artrite psoriasica e dell'uveite. I prodotti in pipeline dell'azienda comprendono anche GLPG1972, che ha completato una sperimentazione di Fase 2b per il trattamento dell'osteoartrite; le molecole Toledo, tra cui GLPG3970, GLPG4399 e GLPG4876 per l'infiammazione; e GLPG4716 e ziritaxestat per il trattamento della fibrosi polmonare idiopatica. Inoltre, gli altri prodotti in pipeline comprendono GLPG2737, un regolatore della conduttanza transmembrana della fibrosi cistica che si trova in sperimentazioni cliniche di Fase 2 per il trattamento di pazienti con malattia renale policistica autosomica dominante; e GLPG0555, un inibitore di JAK1, che si trova in Fase 1b per il trattamento di pazienti con osteoartrite. L'azienda ha accordi di collaborazione con Gilead Sciences, Inc.; AbbVie S.à r.l.; e Novartis Pharma AG. Galapagos NV è stata costituita nel 1999 e ha sede a Mechelen, in Belgio.
| Nome | Galapagos |
| CEO | Henry Gosebruch |
| Sede centrale | Mechelen,
bu Belgio |
| Sito web | |
| Settore | Sanità |
| Industria | Biotecnologia |
| Quotazione in borsa | 06/05/2005 |
| Dipendenti | 452 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Euronext | GLPG.AS |
Pnk | GLPGF |
Amsterdam | GLPG.AS |
Frankfurt | GXE.F |
Düsseldorf | GXE.DU |
London | 0JXZ.L |
München | GXE.MU |
Wien | GLPG.VI |